11554 Background: Many patients with sarcoma deal with adverse impacts on their (QoL) related to their underlying disease as well as treatment-related effects. Unplanned hospital admissions and emergency department (ED) visits occur from uncontrolled symptoms that delay treatment and lead to poor hospital system metrics. The PROMIS Global Health v1.2 (PROMIS-10) survey is a validated tool to assess patients’ physical and mental well-being at the time of the survey, with a higher number indicating a better state of health. There are limited studies evaluating longitudinal QoL assessments during sarcoma treatment. Our objective was to analyze PROMIS-10 scores for patients with advanced sarcoma and their temporal relationship with negative outcomes of interest. Methods: We performed a retrospective registry-based longitudinal analysis of routinely collected PROMIS-10 surveys at The Ohio State University. Patients were consented to the sarcoma registry (NCT02677961) from 6/1/2018 to 12/31/2024. We collected baseline, serial and overall change in physical and mental PROMIS-10 raw and normalized t-scores for each patient during their treatment as well as clinical characteristics, mortality, disease progression (RECIST), and ED visits/unplanned hospital admissions. Survival analyses with time-varying covariates were performed using the marginal Cox model approach for statistical analysis. Results: A total of 241 patients were included in the study. Patients with higher PROMIS-10 physical scores had a 13% decrease in risk of death (HR 0.87; P < 0.001), 3% decrease in risk of progression (HR 0.97; P = 0.027), and 6% decrease in risk of ED visit/unplanned hospital admission (HR 0.94; P < 0.001). Patients with a higher PROMIS-10 mental health score had a 7% decrease in risk of death (HR 0.93; P < 0.001), but no association with disease progression or risk of hospital utilization. The larger positive change in physical PROMIS-10 score from baseline to final assessment was associated with an 11% decreased risk of mortality (HR 0.89; P < 0.001) and 9% decreased risk of ED visit/hospital admission (HR 0.91; P = 0.032), but no association with progression. The larger positive change in mental PROMIS-10 score was associated with a 7% decrease in risk of progression (HR 0.93; P = 0.010) but there was no association with mortality or hospital utilization. Conclusions: We demonstrated that obtaining longitudinal patient-reported outcomes to evaluate patients’ physical and mental health during sarcoma treatment can predict mortality, disease progression and ED visits/unplanned hospital admissions. Higher physical PROMIS-10 scores are strongly associated with decreased mortality and hospital utilization risk, whereas a larger positive change in mental PROMIS-10 scores is associated with decreased risk of progression. To our knowledge, this is the largest cohort (241 patients) of advanced sarcoma analyzing QoL impacts.
Husain et al. (Wed,) studied this question.